… They received either erlotinib or gefitinib once a day. Out of total 28 patients enrolled, 23 …
therapy for metastatic brain tumors during their disease course, either whole brain radiotherapy …

… and 2 patients whole brain radiation. Conclusions: EGFR TKI were effective in NSCLC
patients with brain metastasis harboring either exon 19 or 21 mutations. Exon 19 mutations were …

… benefits for patients with NSCLC and brain metastases. The role of radiotherapy in the … of
intracranial lesions and prolonging the survival than either therapy alone. The benefits seemed …

… However, in our study, treatment method contributed to statistically significant differences
in overall survival of patients with either EGFR exon 19 deletion or 21 point mutation. One of …

… from mNSCLC diagnosis to metastatic bone disease and 1st SRE did not differ either. Post
… 3 EGFR+ patients had an exon 18 mutation and 8 had an exon 20 mutation; these patients …

… incidence of baseline extrathoracic metastasis (P= 0.009), notably brain metastasis (P= …
brain metastasis (P= 0.002) compared by Gray’s test, with estimated 12-month brain metastasis …

… cases (in either primary lung tumors or brain metastases) are … NSCLC and matched brain
metastases are indicated by dots … (n = 25), 56% carried exon 19 deletion mutations, and L858R …

… the probability of developing brain metastasis in the 83 patients with MET exon 14–altered …
which are selective type Ib MET TKIs, are either approved or currently under study in the clinic…

… for developing brain metastases, represented by genetic alterations in either HER2 or EGFR/…
for mutations using either cDNA as template (covering exons 6 to 10 and exons 19 to 20) or …

… In addition, 10 samples were used to sequence exons 3 and 5 for mutations. … exon 4. In
the second tumor, both alleles were mutated, resulting in one product with a deletion of exons 4 …